Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.93 USD | +6.62% | +5.96% | +17.86% |
27/02 | North American Morning Briefing : Stock Futures -2- | DJ |
26/02 | Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating | MT |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Robbins
CEO | Chief Executive Officer | 48 | 23/20/23 |
John Green
DFI | Director of Finance/CFO | 43 | 01/18/01 |
Rachael Easton
CTO | Chief Tech/Sci/R&D Officer | - | 28/22/28 |
Brad Barnett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jessica Sachs
CTO | Chief Tech/Sci/R&D Officer | 49 | 01/17/01 |
John Robinson
CTO | Chief Tech/Sci/R&D Officer | 50 | 06/21/06 |
Christi Waarich
IRC | Investor Relations Contact | - | - |
Dana Martin
PRN | Corporate Officer/Principal | - | 01/21/01 |
Sara Saltzman
LAW | General Counsel | - | 01/19/01 |
Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 26/19/26 |
Matthew Ros
BRD | Director/Board Member | 57 | 26/19/26 |
Todd Shegog
BRD | Director/Board Member | 59 | 22/21/22 |
Karen Ferrante
BRD | Director/Board Member | 66 | 01/18/01 |
Andrew Robbins
CEO | Chief Executive Officer | 48 | 23/20/23 |
Peter Harwin
CHM | Chairman | 38 | 06/20/06 |
Chris Cain
BRD | Director/Board Member | 40 | 06/20/06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 95,613,396 | 94,354,142 ( 98.68 %) | 0 | 98.68 % |
Stock B | 0 | 74,465 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.86% | 621M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- COGT Stock
- Company Cogent Biosciences, Inc.